A cDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika Vaccine
A purified inactivated vaccine (PIV) using the Zika virus (ZIKV) Puerto Rico strain PRVABC59 showed efficacy in monkeys, and is currently in a phase I clinical trial. High-yield manufacture of this PIV is essential for its development and vaccine access. Here we report an infectious cDNA clone-launc...
Main Authors: | Yujiao Yang, Chao Shan, Jing Zou, Antonio E. Muruato, Diniz Nunes Bruno, Barbosa de Almeida Medeiros Daniele, Pedro F.C. Vasconcelos, Shannan L. Rossi, Scott C. Weaver, Xuping Xie, Pei-Yong Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396417300610 |
Similar Items
-
Zika Virus Replicons for Drug Discovery
by: Xuping Xie, et al.
Published: (2016-10-01) -
Zika Virus NS2A-Mediated Virion Assembly
by: Xianwen Zhang, et al.
Published: (2019-10-01) -
Now is the time for the Zika virus
by: Salim Mattar V, et al.
Published: (2015-05-01) -
The Dual Role of the Antibody Response Against the Flavivirus Non-structural Protein 1 (NS1) in Protection and Immuno-Pathogenesis
by: Arturo Reyes-Sandoval, et al.
Published: (2019-07-01) -
Current trends in Zika vaccine development
by: Francisco A. Lagunas-Rangel, et al.
Published: (2017-07-01)